OPKO Health, Inc. Cost of Goods Sold (Deprecated 2018-01-31)
OPKO Health, Inc. (OPK) reported Cost of Goods Sold (Deprecated 2018-01-31) of $14.65 million for the 3-month period ending 2018-03-31, per its 10-Q filed 2018-05-08.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsSold · last filed 2019-01-29
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2018-03-31 was $14.65M, a 1.23% decline year-over-year.
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-12-31 was $16.74M, a 35.56% increase year-over-year.
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-09-30 was $16.11M, a 27.57% increase year-over-year.
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for the quarter ending 2017-06-30 was $13.51M, a 8.32% increase year-over-year.
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2014 was $38.64M, a 0.51% increase from fiscal 2013.
- OPKO Health, Inc. cost of goods sold (deprecated 2018-01-31) for fiscal 2013 was $38.44M.
| Period end | Cost of Goods Sold (Deprecated 2018-01-31) 3 month | Cost of Goods Sold (Deprecated 2018-01-31) 6 month | Cost of Goods Sold (Deprecated 2018-01-31) 9 month | Cost of Goods Sold (Deprecated 2018-01-31) 12 month |
|---|---|---|---|---|
| 2018-03-31 | $14.65M 10-Q · filed 2018-05-08 | $31.38M derived: sum of 2 quarters · filed 2019-01-29 | $47.49M derived: sum of 3 quarters · filed 2019-01-29 | $61.00M derived: sum of 4 quarters · filed 2019-01-29 |
| 2017-12-31 | $16.74M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $32.84M derived: sum of 2 quarters · filed 2019-01-29 | $46.35M derived: sum of 3 quarters · filed 2019-01-29 | $61.18M 8-K · filed 2019-01-29 |
| 2017-09-30 | $16.11M 10-Q · filed 2017-11-08 | $29.61M derived: sum of 2 quarters · filed 2017-11-08 | $44.44M 10-Q · filed 2017-11-08 | $56.79M derived: sum of 4 quarters · filed 2019-01-29 |
| 2017-06-30 | $13.51M 10-Q · filed 2017-08-08 | $28.33M 10-Q · filed 2017-08-08 | $40.68M derived: sum of 3 quarters · filed 2019-01-29 | $53.31M derived: sum of 4 quarters · filed 2019-01-29 |
| 2017-03-31 | $14.83M 10-Q · filed 2018-05-08 | $27.18M derived: sum of 2 quarters · filed 2019-01-29 | $39.80M derived: sum of 3 quarters · filed 2019-01-29 | $52.27M derived: sum of 4 quarters · filed 2019-01-29 |
| 2016-12-31 | $12.35M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $24.97M derived: sum of 2 quarters · filed 2019-01-29 | $37.44M derived: sum of 3 quarters · filed 2019-01-29 | $47.38M 8-K · filed 2019-01-29 |
| 2016-09-30 | $12.63M 10-Q · filed 2017-11-08 | $25.09M derived: sum of 2 quarters · filed 2017-11-08 | $35.03M 10-Q · filed 2017-11-08 | $46.32M derived: sum of 4 quarters · filed 2019-01-29 |
| 2016-06-30 | $12.47M 10-Q · filed 2017-08-08 | $22.41M 10-Q · filed 2017-08-08 | $33.69M derived: sum of 3 quarters · filed 2019-01-29 | $44.35M derived: sum of 4 quarters · filed 2019-01-29 |
| 2016-03-31 | $9.94M 10-Q · filed 2017-05-10 | $21.22M derived: sum of 2 quarters · filed 2019-01-29 | $31.88M derived: sum of 3 quarters · filed 2019-01-29 | $43.81M derived: sum of 4 quarters · filed 2019-01-29 |
| 2015-12-31 | $11.28M derived: 8-K 12 month − 10-Q 9 month · filed 2019-01-29 | $21.94M derived: sum of 2 quarters · filed 2019-01-29 | $33.87M derived: sum of 3 quarters · filed 2019-01-29 | $41.93M 8-K · filed 2019-01-29 |
| 2015-09-30 | $10.66M 10-Q · filed 2016-11-07 | $22.59M derived: sum of 2 quarters · filed 2016-11-07 | $30.65M 10-Q · filed 2016-11-07 | $40.30M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-06-30 | $11.93M 10-Q · filed 2016-08-08 | $19.99M 10-Q · filed 2016-08-08 | $29.64M derived: sum of 3 quarters · filed 2017-03-01 | $38.40M derived: sum of 4 quarters · filed 2017-03-01 |
| 2015-03-31 | $8.06M 10-Q · filed 2016-05-09 | $17.71M derived: sum of 2 quarters · filed 2017-03-01 | $26.47M derived: sum of 3 quarters · filed 2017-03-01 | |
| 2014-12-31 | $9.65M derived: 10-K 12 month − 10-Q 9 month · filed 2017-03-01 | $18.41M derived: sum of 2 quarters · filed 2017-03-01 | $38.64M 10-K · filed 2017-03-01 | |
| 2014-09-30 | $8.76M 10-Q · filed 2015-11-09 | $28.99M 10-Q · filed 2015-11-09 | ||
| 2013-12-31 | $38.44M 10-K · filed 2016-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Jaguar Health, Inc. (JAGX) | United States | $1.184B | |
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |